title: Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sézary syndrome.
authors.affiliation: Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York2Weill Cornell Medical College, New York, New York.
authors.forename: Sarah I
authors.initials: SI
authors.lastname: Jawed
authors.affiliation: Weill Cornell Medical College, New York, New York3Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Klaus
authors.initials: K
authors.lastname: Busam
authors.affiliation: Weill Cornell Medical College, New York, New York3Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Xuan
authors.initials: X
authors.lastname: Wang
authors.affiliation: Weill Cornell Medical College, New York, New York4Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Steven
authors.initials: S
authors.lastname: Horwitz
authors.affiliation: Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York2Weill Cornell Medical College, New York, New York.
authors.forename: Christiane
authors.initials: C
authors.lastname: Querfeld
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D051359:Lymphohistiocytosis, Hemophagocytic / Q000139:chemically induced*; D008875:Middle Aged; D012751:Sezary Syndrome / Q000188:drug therapy*; D012871:Skin Diseases / Q000139:chemically induced*; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074323:Alemtuzumab